7 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 4 Phase 1, 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
Follow Regimen B: new trials by email Literature Review of Regimen B trials Research Report on Regimen B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults RSVpreF (Regimen A), RSVpreF (Regimen B) - Respiratory Syncytial Virus (RSV) | Phase 3 | Not yet recruiting | Pfizer | 750 | 2026-10-29 | 2026-10-21 |
| A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke XY03-EA 150 mg (per dose), XY03-EA 300 mg (Regimen A), XY03-EA 300 mg (Regimen B) - Stroke, Ischemic | Phase 2 | Completed | Shijiazhuang Yiling Pharmaceutical Co. Ltd | 360 | 2024-12-15 | 2026-09-09 |
| Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects Sorafenib - Period 1, XS005 Sorafenib Capsule A - Period 1, XS005 Sorafenib Tablet A - Period 1 - Pharmacokinetics, Bioavailability | Phase 1 | Completed | Xspray Pharma AB | 15 | 2018-11-16 | 2023-08-01 |
| A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010 Regimen A, Regimen B, Regimen C - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Pearl Therapeutics, Inc. | 56 | 2017-10-17 | 2020-06-11 |
| Multi-centre Failed Bowel Prep RCT 4L PegLyte + 15 mg bisacodyl, 6L PegLyte + 15 mg bisacodyl - Colonoscopy, Bowel Preparation | Phase 3 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 196 | 2017-02-13 | 2020-02-21 |
| MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen - Mucopolysaccharidosis Disorders, Hurler Syndrome | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 149 | 2014-07-10 | 2026-01-07 |
| A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route OZ439 120mg PIB, 120 mg OZ439 caplet, 120mg OZ439 caplet via Enterion capsule - Healthy Volunteers | Phase 1 | Completed | Medicines for Malaria Venture | 11 | 2012-11-01 | 2015-03-06 |
| An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor Regimen A, Regimen B, Regimen C - Cancer | Phase 1 | Completed | GlaxoSmithKline | 28 | 2010-10-21 | 2017-11-14 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3) Regimen A, Regimen B, Regimen C - Hematological Malignancies | Phase 2 | Terminated | Medical University of South Carolina | 78 | 2010-06-01 | 2018-07-11 |
| Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma Regimen A, Regimen B - Lymphoma | Phase 2 | Completed | Northwestern University | 25 | 2007-02-06 | 2019-10-15 |
Alpha-Methylacyl-CoA Racemase Deficiency (1) · Aspartylglucosaminuria (1) · Burkitt Lymphoma (1) · Fucosidosis (1) · Hematologic Neoplasms (1) · Hereditary Diffuse Leukoencephalopathy with Spheroids (1) · Ischemic Stroke (1) · Leukodystrophy, Globoid Cell (1) · Leukodystrophy, Metachromatic (1) · Lymphoma (1) · Mucopolysaccharidosis I (1) · Mucopolysaccharidosis II (1) · Mucopolysaccharidosis VI (1) · Mucopolysaccharidosis VII (1) · Neoplasms (1)
GlaxoSmithKline (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Masonic Cancer Center, University of Minnesota (1) · Medical University of South Carolina (1) · Medicines for Malaria Venture (1) · Northwestern University (1) · Pearl Therapeutics, Inc. (1) · Pfizer (1) · Shijiazhuang Yiling Pharmaceutical Co. Ltd (1) · Xspray Pharma AB (1)
United States (5) · United Kingdom (2) · Canada (1) · China (1)
Fiona Macintyre, PhD (1) · Leo Gordon, MD (1) · Michael Sey, MD (1) · Paul M. Dorinsky, MD (1) · Paul Orchard, M.D. (1) · Robert Stuart, MD (1) · Sharan Sidhu, MBChB, BAO, MRCS, MFPM (1)
PMID 23608920, PMID 24146219, PMID 31289092, PMID 32253054, PMID 34256147
P30CA060553 (1)